Regentis Biomaterials Targets Off-the-Shelf Knee Cartilage Repair with GelrinC(R) as Pivotal U.S. Trial Passes 50% Enrollment

Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply and the biological machinery required for meaningful regeneration. For decades, treatment options have reflected that limitation. Microfracture, the long-standing standard of care, attempts to stimulate repair by drilling into the underlying bone in an attempt to mimic a repair trigger. It can provide short-term symptom relief, but long-term cartilage durability remains a recognized challenge with standard treatment. More advanced cell-based therapies exist, but they introduce substantial complexity, cost, manufacturing requirements, and long procedural delays that limit broader adoption. Despite roughly 472,500 arthroscopic knee procedures in the U.S. each year involving knee cartilage damage, the market still lacks an approved, ready-to-use truly regenerative solution capable of combining procedural simplicity with sustained long-term outcomes. Regentis is positioning durability as a central differentiator, with clinical data demonstrating sustained outcomes over extended follow-up periods.

Regentis Biomaterials (NYSE American: RGNT) is targeting that gap with GelrinC(R), its lead regenerative cartilage repair platform designed as a cell-free alternative to conventional treatments. GelrinC(R) is a hydrogel implant that is injected into the knee defect and then solidified in situ using UV light, creating a scaffold that recruits the patient's own cells to regenerate hyaline-like cartilage. The procedure takes approximately 10 minutes and does not require cell harvesting or culturing, making it an off-the-shelf solution. GelrinC(R) already holds CE Mark approval in Europe, and the company's pivotal U.S. FDA trial is now more than 50% enrolled, a significant milestone toward potential market entry.

A key development supporting Regentis' commercial readiness is a newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400%. This innovation signals the company's preparation for commercial scale-up as clinical and regulatory milestones approach. The process eliminates the need for organic solvents, reducing manufacturing complexity and cost while improving consistency and scalability. With the U.S. market lacking an approved off-the-shelf regenerative cartilage repair product, GelrinC(R) could address a substantial unmet need. The company's focus on procedural simplicity and long-term durability aims to overcome the limitations of existing therapies, potentially transforming the standard of care for focal knee cartilage defects.

For more information, visit the company's newsroom at https://ibn.fm/RGNT.